Literature DB >> 19464540

A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

David F Gardiner1, Talia Rosenberg, Jerry Zaharatos, David Franco, David D Ho.   

Abstract

Clostridium difficile is a pathogen with increasing severity for which host antibody responses provide protection from disease. DNA vaccination has several advantages compared to traditional vaccine methods, however no study has examined this platform against C. difficile toxins. A synthetic gene was created encoding the receptor-binding domain (RBD) of C. difficile toxin A, optimized for expression in human cells. Gene expression was examined in vitro. Mice were inoculated and then challenged with parenteral toxin A. Vaccination provided high titer antibodies and protected mice from death. This represents the first report of DNA vaccine inducing neutralizing antibodies to C. difficile toxin A.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464540      PMCID: PMC2709243          DOI: 10.1016/j.vaccine.2009.03.058

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  76 in total

Review 1.  Vaccine delivery methods using viral vectors.

Authors:  Andreas Bråve; Karl Ljungberg; Britta Wahren; Margaret A Liu
Journal:  Mol Pharm       Date:  2007 Jan-Feb       Impact factor: 4.939

Review 2.  Delivery of DNA vaccines using electroporation.

Authors:  Shawn Babiuk; Sylvia van Drunen Littel-van den Hurk; Lorne A Babiuk
Journal:  Methods Mol Med       Date:  2006

Review 3.  Needle-free liquid jet injections: mechanisms and applications.

Authors:  Joy Baxter; Samir Mitragotri
Journal:  Expert Rev Med Devices       Date:  2006-09       Impact factor: 3.166

4.  Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.

Authors:  Xinghong Yang; B Joseph Hinnebusch; Theresa Trunkle; Catharine M Bosio; Zhiyong Suo; Mike Tighe; Ann Harmsen; Todd Becker; Kathryn Crist; Nancy Walters; Recep Avci; David W Pascual
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

5.  Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier.

Authors:  Jia-Yu Chen; Fan Li
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 6.  Use of attenuated bacteria as delivery vectors for DNA vaccines.

Authors:  Damini Daudel; Gerald Weidinger; Simone Spreng
Journal:  Expert Rev Vaccines       Date:  2007-02       Impact factor: 5.217

7.  Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant.

Authors:  Yaoxing Huang; Zhiwei Chen; Wenyong Zhang; Deborah Gurner; Yang Song; David F Gardiner; David D Ho
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-01       Impact factor: 3.731

Review 8.  Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases.

Authors:  Deborah H Fuller; Peter Loudon; Connie Schmaljohn
Journal:  Methods       Date:  2006-09       Impact factor: 3.608

9.  Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.

Authors:  Gregory J Babcock; Teresa J Broering; Hector J Hernandez; Robert B Mandell; Katherine Donahue; Naomi Boatright; Anne M Stack; Israel Lowy; Robert Graziano; Deborah Molrine; Donna M Ambrosino; William D Thomas
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

10.  Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A.

Authors:  Claribel P Taylor; Sanjeev Tummala; Deborah Molrine; Lisa Davidson; Richard J Farrell; Anthony Lembo; Patricia L Hibberd; Israel Lowy; Ciaran P Kelly
Journal:  Vaccine       Date:  2008-05-07       Impact factor: 3.641

View more
  38 in total

1.  An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.

Authors:  Scott M Baliban; Amanda Michael; Berje Shammassian; Shikata Mudakha; Amir S Khan; Simon Cocklin; Isaac Zentner; Brian P Latimer; Laurent Bouillaut; Meredith Hunter; Preston Marx; Niranjan Y Sardesai; Seth L Welles; Jeffrey M Jacobson; David B Weiner; Michele A Kutzler
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

2.  Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.

Authors:  Xiaohong Jiang; Tim J Dalebout; Igor S Lukashevich; Peter J Bredenbeek; David Franco
Journal:  J Gen Virol       Date:  2014-12-16       Impact factor: 3.891

Review 3.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

Review 4.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

Review 5.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

6.  Clostridium difficile-induced colitis in mice is independent of leukotrienes.

Authors:  Bruno C Trindade; Casey M Theriot; Jhansi L Leslie; Paul E Carlson; Ingrid L Bergin; Marc Peters-Golden; Vincent B Young; David M Aronoff
Journal:  Anaerobe       Date:  2014-09-16       Impact factor: 3.331

7.  Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice.

Authors:  Sergey S Seregin; Yasser A Aldhamen; David P W Rastall; Sarah Godbehere; Andrea Amalfitano
Journal:  Vaccine       Date:  2011-12-23       Impact factor: 3.641

8.  Protective efficacy induced by recombinant Clostridium difficile toxin fragments.

Authors:  Rosanna Leuzzi; Janice Spencer; Anthony Buckley; Cecilia Brettoni; Manuele Martinelli; Lorenza Tulli; Sara Marchi; Enrico Luzzi; June Irvine; Denise Candlish; Daniele Veggi; Werner Pansegrau; Luigi Fiaschi; Silvana Savino; Erwin Swennen; Osman Cakici; Ernesto Oviedo-Orta; Monica Giraldi; Barbara Baudner; Nunzia D'Urzo; Domenico Maione; Marco Soriani; Rino Rappuoli; Mariagrazia Pizza; Gillian R Douce; Maria Scarselli
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

Review 9.  Clostridium difficile Infection in Children: Current State and Unanswered Questions.

Authors:  Pranita D Tamma; Thomas J Sandora
Journal:  J Pediatric Infect Dis Soc       Date:  2012-07-25       Impact factor: 3.164

10.  Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.

Authors:  Zhiyong Yang; Lianfa Shi; Hua Yu; Yongrong Zhang; Kevin Chen; Ashley Saint Fleur; Guang Bai; Hanping Feng
Journal:  Pathog Dis       Date:  2016-08-07       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.